STAFF BOARD
Article
CHAIRMAN
Virginia Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Jaime E. Poquet Jornet
MARKETING MANAGER
EDITORIAL BOARD
Ramón Jódar Masanés
Lluís Campins Bernadas
Tomás Casasín Edo
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 21 - Issue 4, October-December 2019
ORIGINAL
INVESTIGATION OF PREVENTIVE EFFECTS OF MAGNESIUM OXIDE FOR PANITUMUMAB-RELATED HYPOMAGNESEMIA
TANAKA REI, ISHIKAWA HIROSHI, SATO JUNYA, SHINO MICHIHIRO, AOYAMA TAKAO, YAMAZAKI KENTARO


Hypomagnesemia is an adverse event that frequently occurs as a result of anti-
EGFR antibodies therapy such as panitumumab. In order to enable the complete
implementation of treatment, it is very important to prevent hypomagnesemia.
While the use of oral magnesium agents, which are safer and simpler to administer
than injections, is ideal for preventing this condition, the effects of such agents
have not been sufficiently reported. Therefore, we investigated the preventive
effects of the oral administration of magnesium oxide for panitumumab-related
hypomagnesemia.
We divided our subjects, comprising 86 cases of wild-type KRAS unresectable
colorectal cancer administered panitumumab at the Shizuoka Cancer Center between
April 2010 and March 2016, into a magnesium oxide concomitant group (concomitant
group) and a non-concomitant group. We then retrospectively investigated
hypomagnesemia incidence and severity (CTCAE ver. 4.0) within six weeks from
the start of panitumumab administration, as well as over the entire treatment period.
The 86 subjects comprised 24 subjects in the concomitant group and 62 subjects
in the non-concomitant group. Hypomagnesemia incidence within six weeks from
the start of panitumumab administration was 16.7% in the concomitant group
and 41.9% in the non-concomitant group (p = 0.042), while severity (Gr1/2/3/4)
was 2/2/0/0 patients in the concomitant group and 23/3/0/0 patients in the non-concomitant group (p = 0.043), both indicating significant differences. Over the entire
treatment period, however, incidence was 41.7% in the concomitant group
and 51.6% in the non-concomitant group (p = 0.475), while severity (Gr1/2/3/4)
was 7/3/0/0 patients in the concomitant group and 25/6/1/0 patients in the non-concomitant group (p = 0.505), indicating no significant differences.
The concomitant use of magnesium oxide might reduce the incidence and severity
of panitumumab-related hypomagnesemia within six weeks after starting
administration, although no long-term preventive effects were confirmed.

COLORECTAL CANCER – HYPOMAGNESEMIA – MAGNESIUM OXIDE – PANITUMUMAB



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25